查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1530795

2030 年醫藥市場預測：按產品類型、給藥途徑、治療領域、最終用戶和地區進行的全球分析

Pharmaceuticals Market Forecasts to 2030 - Global Analysis By Product Type (Branded Drugs, Generic Drugs, OTC Drugs, Biopharmaceuticals, Vaccines and Other Product Types), Route of administration, Therapy Area, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球醫藥市場規模將達到 16 億美元，預計 2030 年將達到 26 億美元，預測期內複合年成長率為 8.4%。

藥品是為診斷、治療、預防和緩解疾病而開發的藥物。該領域涵蓋新化合物從發現到開發、測試、監管核准、生產和分銷的整個過程。藥品包括多種產品，從非處方藥到處方藥、疫苗和生技藥品。該行業受到嚴格監管，需要進行廣泛的研究、臨床試驗並遵守 FDA 等權威機構制定的標準，以確保藥品的安全性、有效性和品質。藥物在現代醫療保健中發揮重要作用，可以管理各種健康狀況，改善患者的治療效果，並為公共衛生做出貢獻。

慢性病增加

慢性病盛行率的不斷上升推動了對持續用藥、專門治療和創新治療的需求，從而導致製藥公司的銷售和收益增加。這一趨勢也刺激了研發投資，促進了新藥和改良藥物的創造。此外，業界為應對複雜的健康挑戰而建立的聯盟和合作也在不斷發展，從而促進了市場成長。

藥價上漲的社會監測

公眾監督可能會導致監管壓力和旨在遏製或降低藥品價格的立法行動增加。它還可能導致聲譽受損並影響股價和投資者信心。公司可能面臨較低的利潤率，從而阻礙新藥研發的投資並阻礙預測期內的成長。

政府增加醫療保健支出

政府投資的增加將加強醫療基礎設施並支持基本藥物的廣泛分配，從而增加製藥公司的需求和銷售。它還資助研究和開發舉措，並促進創新和新治療方法的引進。此外，政府支出通常包括津貼和報銷計劃，使患者更能負擔得起藥品並促進市場成長。

學名藥競爭

當品牌藥的專利到期時，學名藥製造商能夠生產和銷售品牌藥的廉價版本，導致品牌藥的銷售量急劇下降。學名藥的存在迫使品牌藥品製造商在行銷和創新方面投入更多資金，以實現產品差異化，從而增加營運成本。

COVID-19 的影響：

COVID-19大流行對醫藥市場產生了重大影響，加速了技術創新以及疫苗和治療方法的發展。它增加了對藥物、診斷和醫療保健用品的需求，提高了許多公司的收益。但它也擾亂了供應鏈、推遲了臨床試驗並導致資源緊張。這場危機凸顯了該行業敏捷性和協作的重要性，從而導致快速進展並重新關注全球衛生準備和抵禦未來流行病的能力。

品牌藥品市場預計在預測期內成為最大的市場

品牌藥品受專利保護，使製藥公司能夠收回研發成本並為進一步創新提供資金。品牌藥品通常價格高昂，為製造商帶來可觀的收益和利潤，對於推進治療方法和解決未滿足的醫療保健需求至關重要。

癌症領域預計在預測期內複合年成長率最高

由於全球癌症發生率高，對有效治療的需求不斷增加，使得腫瘤學成為製藥公司的首要任務。這種關注導致了標靶治療、免疫療法和個人化醫療等創新治療方法的發展，這些療法價格高昂，並產生可觀的收益，確保了行業內的持續成長和創新。

佔比最大的地區：

預計北美在預測期內將佔據最大的市場佔有率北美，尤其是美國，佔據全球醫藥市場的大部分。該市場的特點是人口老化、慢性病盛行率上升以及對創新治療的高需求推動的強勁成長。此外，該地區是醫藥創新領域的領導者，並在研發方面投入大量資金。

複合年成長率最高的地區：

預計亞太地區在預測期內將保持最高的複合年成長率，因為由於醫療保健需求的增加、可支配收入的增加和醫療保健服務範圍的擴大，該地區正在顯著成長。中國和印度等國家因其龐大的人口和發達的醫療基礎設施而對這一成長做出了重大貢獻。當地企業是學名藥市場的主要參與者，為該地區製藥業的成長做出了貢獻。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球醫藥市場：依產品類型

  • 品牌藥品
  • 學名藥
  • 非處方藥
  • 生物製藥
  • 疫苗
  • 其他產品類型

第6章全球醫藥市場：依途徑

  • 口服
    • 錠劑
    • 膠囊
    • 液體
    • 糖漿
  • 注射
    • 靜脈
    • 肌肉注射
    • 皮下的
    • 滴
  • 話題
    • 奶油
    • 軟膏
    • 凝膠
    • 修補
  • 吸入
    • 定量吸入器
    • 乾粉吸入器
    • 噴霧器
  • 經皮的
  • 鼻腔
  • 其他給藥途徑

第7章全球醫藥市場：依治療領域

  • 腫瘤學
  • 心血管疾病
  • 神經病學
  • 呼吸系統疾病
  • 胃腸道疾病
  • 感染疾病
  • 糖尿病
  • 其他治療領域

第8章全球製藥市場：依最終用戶分類

  • 診所
  • 醫院
  • 居家照護環境
  • 研究/學術機構
  • 其他最終用戶

第9章全球醫藥市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章 公司概況

  • Pfizer Inc.
  • Johnson & Johnson
  • Roche Holding AG
  • Novartis International AG
  • Merck & Co., Inc.（MSD）
  • Bristol-Myers Squibb
  • Sanofi
  • GlaxoSmithKline
  • AstraZeneca
  • AbbVie Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim
  • Gilead Sciences, Inc.
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • Biogen Inc.
Product Code: SMRC26907

According to Stratistics MRC, the Global Pharmaceuticals Market is accounted for $1.6 billion in 2024 and is expected to reach $2.6 billion by 2030 growing at a CAGR of 8.4% during the forecast period. Pharmaceuticals are drugs and medications developed for use in medical diagnosis, treatment, prevention, and alleviation of diseases. This field encompasses the entire process from the discovery of new compounds to their development, testing, regulatory approval, production, and distribution. Pharmaceuticals include a wide range of products, from over-the-counter drugs to prescription medications, vaccines, and biologics. The industry is highly regulated to ensure drug safety, efficacy, and quality, requiring extensive research, clinical trials, and adherence to standards set by authorities like the FDA. Pharmaceuticals play a critical role in modern healthcare, enabling the management of various health conditions, enhancing patient outcomes, and contributing to public health.

Market Dynamics:

Driver:

Increasing incidence of chronic diseases increases

Increasing incidence of chronic diseases drives demand for ongoing medication, specialized treatments, and innovative therapies, leading to higher sales and revenue growth for pharmaceutical companies. This trend also stimulates research and development investments, fostering the creation of new and improved drugs. Additionally, it encourages partnerships and collaborations within the industry to address complex health challenges propelling the markets growth.

Restraint:

Public scrutiny of high drug prices

Public scrutiny can lead to increased regulatory pressure and legislative actions aimed at controlling or reducing drug prices. It may also result in reputational damage, affecting stock prices and investor confidence. Companies might face reduced profit margins, hampering their ability to invest in research and development for new drugs hampering its growth during the forecast period.

Opportunity:

Increased government spending on healthcare

Increased government nvestment enhances healthcare infrastructure and supports broader distribution of essential drugs, driving higher demand and sales for pharmaceutical companies. It also funds research and development initiatives, fostering innovation and the introduction of new therapies. Moreover, government spending often includes subsidies and reimbursement programs, making medications more affordable for patients encouraging growth of the market.

Threat:

Generic competition

Patents for branded drugs expire, generic drug makers can produce and sell cheaper versions of these medications, leading to a sharp decline in the sales of the original products. This increased availability of lower-cost alternatives drives down prices across the market, reducing profit margins for both brand-name and generic pharmaceutical companies thereby the presence of generics also forces branded drug manufacturers to invest more in marketing and innovation to differentiate their products, increasing operational costs.

Covid-19 Impact:

The COVID-19 pandemic profoundly impacted the pharmaceuticals market, accelerating innovation and the development of vaccines and treatments. It increased demand for medications, diagnostics, and healthcare supplies, boosting revenues for many companies. However, it also disrupted supply chains, delayed clinical trials, and strained resources. The crisis emphasized the importance of agility and collaboration in the industry, leading to rapid advancements and a renewed focus on global health preparedness and resilience against future pandemics.

The branded drugs segment is expected to be the largest during the forecast period

The branded drugs is expected to be the largest during the forecast period because these drugs, protected by patents, allow pharmaceutical companies to recoup research and development costs and fund further innovation. They often command higher prices, contributing to substantial revenue and profitability for their manufacturers and branded drugs remain crucial for advancing medical treatments and addressing unmet healthcare needs.

The oncology segment is expected to have the highest CAGR during the forecast period

The oncology segment is expected to have the highest CAGR during the forecast period owing to the high prevalence of cancer worldwide creates substantial demand for effective treatments, positioning oncology as a top priority for pharmaceutical companies. This focus leads to the development of innovative therapies, including targeted treatments, immunotherapy's, and personalized medicine, which command high prices and generate substantial revenue ensuring sustained growth and innovation within the industry.

Region with largest share:

North America is projected to hold the largest market share during the forecast period North America, particularly the U.S., represents a significant portion of the global pharmaceuticals market. The market is characterized by strong growth due to aging populations, increasing prevalence of chronic diseases, and high demand for innovative treatments. Further the region is a leader in pharmaceutical innovation, with substantial investments in research and development.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period as the Asia-Pacific region is experiencing significant growth due to increasing healthcare needs, rising disposable incomes, and expanding access to healthcare services. Countries like China and India are major contributors to this growth, with their large populations and improving healthcare infrastructure. Local companies are major players in the generic drug market, contributing to the region's growing pharmaceutical industry.

Key players in the market

Some of the key players in Pharmaceuticals market include Pfizer Inc., Johnson & Johnson, Roche Holding AG, Novartis International AG, Merck & Co., Inc. (MSD), Bristol-Myers Squibb, Sanofi, GlaxoSmithKline, AstraZeneca, AbbVie Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Gilead Sciences, Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc. and Biogen Inc.

Key Developments:

In July 2024, Johnson & Johnson strengthened pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics. The company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases

In June 2024, Pfizer Inc. and BioNTech received positive CHMP opinion for Omicron JN.1-adapted COVID-19 vaccine in the European Union. The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older

In June 2024, Bayer receives breakthrough therapy designation in China for BAY 2927088 in high unmet need patients with HER2-mutant non-small cell lung cancer. The Center for Drug Evaluation in China has granted breakthrough therapy designation to expedite the development

Product Types Covered:

  • Branded Drugs
  • Generic Drugs
  • OTC (Over-the-Counter) Drugs
  • Biopharmaceuticals
  • Vaccines
  • Other Product Types

Route of administrations Covered:

  • Oral
  • Injectable
  • Topical
  • Inhalation
  • Transdermal
  • Nasal
  • Other Route of administrations

Therapy Areas Covered:

  • Oncology
  • Cardiovascular Diseases
  • Neurology
  • Respiratory Diseases
  • Gastrointestinal Disorders
  • Infectious Diseases
  • Diabetes
  • Other Therapy Areas

End Users Covered:

  • Clinics
  • Hospitals
  • Home Care Settings
  • Research & Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmaceuticals Market, By Product Type

  • 5.1 Introduction
  • 5.2 Branded Drugs
  • 5.3 Generic Drugs
  • 5.4 OTC (Over-the-Counter) Drugs
  • 5.5 Biopharmaceuticals
  • 5.6 Vaccines
  • 5.7 Other Product Types

6 Global Pharmaceuticals Market, By Route of administration

  • 6.1 Introduction
  • 6.2 Oral
    • 6.2.1 Tablets
    • 6.2.2 Capsules
    • 6.2.3 Liquids
    • 6.2.4 Syrups
  • 6.3 Injectable
    • 6.3.1 Intravenous
    • 6.3.2 Intramuscular
    • 6.3.3 Subcutaneous
    • 6.3.4 Infusions
  • 6.4 Topical
    • 6.4.1 Creams
    • 6.4.2 Ointments
    • 6.4.3 Gels
    • 6.4.4 Patches
  • 6.5 Inhalation
    • 6.5.1 Metered-Dose Inhalers
    • 6.5.2 Dry Powder Inhalers
    • 6.5.3 Nebulizers
  • 6.6 Transdermal
  • 6.7 Nasal
  • 6.8 Other Route of administrations

7 Global Pharmaceuticals Market, By Therapy Area

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Cardiovascular Diseases
  • 7.4 Neurology
  • 7.5 Respiratory Diseases
  • 7.6 Gastrointestinal Disorders
  • 7.7 Infectious Diseases
  • 7.8 Diabetes
  • 7.9 Other Therapy Areas

8 Global Pharmaceuticals Market, By End User

  • 8.1 Introduction
  • 8.2 Clinics
  • 8.3 Hospitals
  • 8.4 Home Care Settings
  • 8.5 Research & Academic Institutes
  • 8.6 Other End Users

9 Global Pharmaceuticals Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Pfizer Inc.
  • 11.2 Johnson & Johnson
  • 11.3 Roche Holding AG
  • 11.4 Novartis International AG
  • 11.5 Merck & Co., Inc. (MSD)
  • 11.6 Bristol-Myers Squibb
  • 11.7 Sanofi
  • 11.8 GlaxoSmithKline
  • 11.9 AstraZeneca
  • 11.10 AbbVie Inc.
  • 11.11 Eli Lilly and Company
  • 11.12 Bayer AG
  • 11.13 Amgen Inc.
  • 11.14 Takeda Pharmaceutical Company Limited
  • 11.15 Boehringer Ingelheim
  • 11.16 Gilead Sciences, Inc.
  • 11.17 Novo Nordisk A/S
  • 11.18 Teva Pharmaceutical Industries Ltd.
  • 11.19 Astellas Pharma Inc.
  • 11.20 Biogen Inc.

List of Tables

  • Table 1 Global Pharmaceuticals Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Pharmaceuticals Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Pharmaceuticals Market Outlook, By Branded Drugs (2022-2030) ($MN)
  • Table 4 Global Pharmaceuticals Market Outlook, By Generic Drugs (2022-2030) ($MN)
  • Table 5 Global Pharmaceuticals Market Outlook, By OTC (Over-the-Counter) Drugs (2022-2030) ($MN)
  • Table 6 Global Pharmaceuticals Market Outlook, By Biopharmaceuticals (2022-2030) ($MN)
  • Table 7 Global Pharmaceuticals Market Outlook, By Vaccines (2022-2030) ($MN)
  • Table 8 Global Pharmaceuticals Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 9 Global Pharmaceuticals Market Outlook, By Route of administration (2022-2030) ($MN)
  • Table 10 Global Pharmaceuticals Market Outlook, By Oral (2022-2030) ($MN)
  • Table 11 Global Pharmaceuticals Market Outlook, By Tablets (2022-2030) ($MN)
  • Table 12 Global Pharmaceuticals Market Outlook, By Capsules (2022-2030) ($MN)
  • Table 13 Global Pharmaceuticals Market Outlook, By Liquids (2022-2030) ($MN)
  • Table 14 Global Pharmaceuticals Market Outlook, By Syrups (2022-2030) ($MN)
  • Table 15 Global Pharmaceuticals Market Outlook, By Injectable (2022-2030) ($MN)
  • Table 16 Global Pharmaceuticals Market Outlook, By Intravenous (2022-2030) ($MN)
  • Table 17 Global Pharmaceuticals Market Outlook, By Intramuscular (2022-2030) ($MN)
  • Table 18 Global Pharmaceuticals Market Outlook, By Subcutaneous (2022-2030) ($MN)
  • Table 19 Global Pharmaceuticals Market Outlook, By Infusions (2022-2030) ($MN)
  • Table 20 Global Pharmaceuticals Market Outlook, By Topical (2022-2030) ($MN)
  • Table 21 Global Pharmaceuticals Market Outlook, By Creams (2022-2030) ($MN)
  • Table 22 Global Pharmaceuticals Market Outlook, By Ointments (2022-2030) ($MN)
  • Table 23 Global Pharmaceuticals Market Outlook, By Gels (2022-2030) ($MN)
  • Table 24 Global Pharmaceuticals Market Outlook, By Patches (2022-2030) ($MN)
  • Table 25 Global Pharmaceuticals Market Outlook, By Inhalation (2022-2030) ($MN)
  • Table 26 Global Pharmaceuticals Market Outlook, By Metered-Dose Inhalers (2022-2030) ($MN)
  • Table 27 Global Pharmaceuticals Market Outlook, By Dry Powder Inhalers (2022-2030) ($MN)
  • Table 28 Global Pharmaceuticals Market Outlook, By Nebulizers (2022-2030) ($MN)
  • Table 29 Global Pharmaceuticals Market Outlook, By Transdermal (2022-2030) ($MN)
  • Table 30 Global Pharmaceuticals Market Outlook, By Nasal (2022-2030) ($MN)
  • Table 31 Global Pharmaceuticals Market Outlook, By Other Route of administrations (2022-2030) ($MN)
  • Table 32 Global Pharmaceuticals Market Outlook, By Therapy Area (2022-2030) ($MN)
  • Table 33 Global Pharmaceuticals Market Outlook, By Oncology (2022-2030) ($MN)
  • Table 34 Global Pharmaceuticals Market Outlook, By Cardiovascular Diseases (2022-2030) ($MN)
  • Table 35 Global Pharmaceuticals Market Outlook, By Neurology (2022-2030) ($MN)
  • Table 36 Global Pharmaceuticals Market Outlook, By Respiratory Diseases (2022-2030) ($MN)
  • Table 37 Global Pharmaceuticals Market Outlook, By Gastrointestinal Disorders (2022-2030) ($MN)
  • Table 38 Global Pharmaceuticals Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 39 Global Pharmaceuticals Market Outlook, By Diabetes (2022-2030) ($MN)
  • Table 40 Global Pharmaceuticals Market Outlook, By Other Therapy Areas (2022-2030) ($MN)
  • Table 41 Global Pharmaceuticals Market Outlook, By End User (2022-2030) ($MN)
  • Table 42 Global Pharmaceuticals Market Outlook, By Clinics (2022-2030) ($MN)
  • Table 43 Global Pharmaceuticals Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 44 Global Pharmaceuticals Market Outlook, By Home Care Settings (2022-2030) ($MN)
  • Table 45 Global Pharmaceuticals Market Outlook, By Research & Academic Institutes (2022-2030) ($MN)
  • Table 46 Global Pharmaceuticals Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.